Center for Global Health R&D Policy Assessment

The New Innovation Fund aims to benefit local R&D in the pharmaceutical sector and to improve market competitiveness. This fund would be a national level fund for R&D focusing on orphan and neglected diseases that would require all beneficiaries to license their technologies to generic manufacturers.

The proponents pose two possibilities—the first offers innovators less project support and a two year monopoly period and the second offers a much higher level of financing but no period of market exclusivity. Resources to support the fund would be collected from licensing royalties, novel taxes, government R&D budgets and voluntary contributions.